Cantor Fitzgerald analyst Charles Duncan maintains $Alkermes (ALKS.US)$ with a buy rating, and adjusts the target price from $48 to $43.
According to TipRanks data, the analyst has a success rate of 50.7% and a total average return of 24.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
Alkermes reported third-quarter results that were generally consistent with expectations and maintained its 2024 outlook. However, the emphasis during the earnings call was on management's indication that 2025 EBITDA is anticipated to exceed $200M, contrasting with a general expectation of $400M. This discrepancy in EBITDA compared to consensus figures seems to be primarily due to the anticipated loss of high-margin royalty revenues, along with increased spending to some degree.
Alkermes' Q3 performance reflected a mix of outcomes from its existing commercial suite, which overall aligned with expectations. The company is proactively channeling its investments towards ALKS-2680 and exploring the broad possibilities presented by its orexin-2 receptor agonist pipeline. Despite the near-term influence moderating profit prospects, there is optimism regarding the long-term value generation prospects of ALKS-2680.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析师Charles Duncan维持$阿尔凯默斯 (ALKS.US)$买入评级，并将目标价从48美元下调至43美元。
根据TipRanks数据显示，该分析师近一年总胜率为50.7%，总平均回报率为24.2%。
此外，综合报道，$阿尔凯默斯 (ALKS.US)$近期主要分析师观点如下：
阿尔凯默斯报告了与预期基本一致的第三季度业绩，并维持了其2024年的展望。然而，在业绩会上重点关注了管理层预计2025年EBITDA将超过$20000万的表示，与总体预期的$40000万形成鲜明对比。与共识数据相比，EBITDA存在的这种差异似乎主要是由于高利润版税收入预期损失以及在一定程度上增加支出所致。
阿尔凯默斯的第三季度表现反映了其现有商业套件的结果混合，总体与预期一致。该公司正在积极将投资导向ALKS-2680，并探索其觉醒素-2受体激动剂管线所带来的广泛可能性。尽管近期影响会减弱利润前景，但对ALKS-2680的长期价值创造前景仍持乐观态度。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
